Search for a trial

Vitamin c to Improve Tissue healing by Administration of Multiple INtravenous dosages

PrimaryImproved woundhealing in 30 days in patients with an open revascularisation of the lower extremities after treatment with 4 dosages of 2 grams ascorbic acid on 4 consecutive days. (First dosage 1 hour preoperative)SecondaryWith preoperative…

Double-blinded, randomised, placebo-controlled, multicentre , Phase IIa study to investigate the effect, safety and tolerability of phosphorylcholine human monoclonal antibody (PC-mAb) 3G10 on arterial inflammation, together with safety and tolerability, in subjects with elevated lipoprotein a (Lp[a ])

1. The primary objective is to assess the effects of four 250 mg PC-mAB (also referred to as "3G10") once monthly intravenous injections on monocyte function ex vivo. The secondary objectives are to:1. assess the functional effects of 3G10…

The effect of hesperidin administration on endothelial function and gut barrier function

To determine the chronic and acute effects of daily administration of hesperidin on cardiovascular and intestinal health as assessed by investigation of endothelial function, blood pressure, heart rate, glucose/insulin metabolism, lipid metabolism…

The effects of oligomeric procyanidins (OPCs) on vascular function, biomarkers of oxidative stress and inflammation in smokers: a pilot study

To evaluate the potential attenuating effects of an eight-week supplementation with 200 mg OPCs per day on macro- and microvascular function as well as on systemic biomarkers of inflammation and oxidative stress in healthy smoking subjects.

A Long-Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia (STRENGTH)

Primary ObjectiveThe primary objective is to evaluate the effectiveness of adding Epanova to statin therapy (with or without ezetimibe) for lowering MACE (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, emergent/elective…

A long term, randomised, double blind, placebo-controlled study to determine the effect of albiglutide, when added to standard blood glucose lowering therapies, on major cardiovascular events in patients with Type 2 diabetes mellitus (Harmony Outcomes Trial, GLP116174)

Primary: Time to first occurrence of MACE (cardiovascular death, myocardial infarction, or stroke) [Non-inferiority].Secondary: Time to first occurrence of MACE [Superiority], MACE or urgent revascularization for unstable angina, individual…